NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President and Chief Executive Officer
June 13 2016 - 5:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a
biopharmaceutical company focusing on commercializing prescription
Avenova® lid and lash hygiene for the domestic eye care market,
announces the appointment of Mark M. Sieczkarek as President and
Chief Executive Officer, effectively immediately. Sieczkarek has
been a NovaBay Director since January 2014, was named Chairman in
April 2015 and has served as interim President and CEO since
November 2015. He has been instrumental in the development and
implementation of the go-to-market strategy for Avenova.
“I’m delighted to take on the executive responsibilities on a
permanent basis and am fully committed to the successful
commercialization of Avenova,” said Sieczkarek. “I’m proud of our
team’s many fast-paced activities to advance the marketing strategy
and appreciate the support from our Board in pursuing our goals.
With our new strategy now in place, expense management in hand, a
strengthened balance sheet and long-term committed investors, we
are on track to achieve our target of positive cash flow from
operations by the end of 2016 and accelerated revenue growth
beyond.”
Mr. Sieczkarek previously was CEO of Solta Medical, Inc.
(acquired by Valeant Pharmaceuticals) and of Conceptus, Inc.
(acquired by Bayer HealthCare), where he led the launch of the
medical device Essure®. Prior to that, he was Senior Vice President
and President of The Americas and Europe for the leading ophthalmic
company Bausch & Lomb (acquired by Valeant Pharmaceuticals),
where he was responsible for overseeing multinational commercial
launches of several leading products.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics
NovaBay Pharmaceuticals is a biopharmaceutical company focusing
on the commercialization of prescription Avenova® lid and lash
hygiene for the eye care market. Avenova is formulated with
Neutrox™, which is cleared by the U.S. Food and Drug Administration
(FDA) as a 510(k) medical device. Neutrox is NovaBay’s pure
hypochlorous acid. Laboratory tests show that pure hypochlorous
acid has potent antimicrobial activity in solution yet is non-toxic
to mammalian cells and it also neutralizes bacterial toxins. Data
from a multicenter clinical study show that Avenova reduced
bacterial load, the underlying cause of blepharitis, on ocular skin
surface by more than 90%. Avenova is marketed to optometrists and
ophthalmologists throughout the U.S. by NovaBay’s direct medical
salesforce. It is accessible from more than 90% of retail
pharmacies in the U.S. through agreements with McKesson
Corporation, Cardinal Health and AmeriSource Bergen.
Forward-Looking Statements
This release contains forward-looking statements, which are
based upon management's current expectations, assumptions,
estimates, projections and beliefs. These statements include,
but are not limited to, statements regarding our ability to become
cash flow positive by the end of 2016, future sales of our
products, the ability to raise additional capital through warrant
exercises, and the Company’s expected future financial results.
Forward-looking statements can be identified with words like (and
variations of): “estimate,” “believe,” and “expect.” These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to difficulties or delays in
manufacturing, distributing, and selling the Company's products,
unexpected adverse side effects or inadequate therapeutic efficacy
of our product, the uncertainty of patent protection for the
Company's intellectual property, and the Company's ability to
obtain additional financing as necessary. Other risks relating
to NovaBay’s business, including risks that could cause results to
differ materially from those projected in the forward-looking
statements in this press release, are detailed in NovaBay's latest
Form 10-K and Form 10-Q filings with the Securities and Exchange
Commission, especially under the heading "Risk Factors." The
forward-looking statements in this release speak only as of this
date, and NovaBay disclaims any intent or obligation to revise or
update publicly any forward-looking statement except as required by
law.
Stay informed on NovaBay's
progress:
Download our Mobile InvestorApp from the Apple
Store or Google PlayLike us on
FacebookFollow us on TwitterConnect with
NovaBay on LinkedInJoin us on
Google+Visit NovaBay's Website
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160613005243/en/
NovaBay ContactsFor NovaBay
Avenova purchasing information, please contact:Email usCall us:
1-800-890-0329www.Avenova.comorFrom the
CompanyThomas J. Paulson, 510-899-8809Chief Financial
OfficerContact TomorInvestor
ContactLHAJody Cain, 310-691-7100Jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2024 to May 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024